Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks on April 28, 2025 Aggressive disease treatments Fibromatosis Gomekli KGaA Merck KGaA Neurofibromatosis 1 Ogsiveo Pfizer pharmaceutical acquisition SpringWorks +
Merck KGaA closes in on SpringWorks deal at $3.5B price point on April 25, 2025 Acquisition (action) deal Gomekli Infrequent KGaA Merck SpringWorks +
FDA Approves SpringWorks' Gomekli for Adult and Pediatric NF1-PN Patients on February 13, 2025 Approved Gomekli Inhibitor MEK mirdametinib neurofibroma Plexiform SpringWorks United States Food and Drug Administration +
SpringWorks Therapeutics Secures FDA Approval for Gomekli to Treat NF1-Related Tumors on February 12, 2025 Approved disease treatment Gomekli Infrequent Inhibitor MEK mirdametinib Neurofibromatosis 1 Plexiform Plexiform Neurofibroma SpringWorks United States Food and Drug Administration +
Merck KGaA in Advanced Talks to Acquire SpringWorks Therapeutics, Bolstering Oncology Portfolio on February 12, 2025 Acquisition Drug Industry Gomekli Merck KGaA Neoplasms Ogsiveo SpringWorks +